{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-006457","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.331025+00:00","generated_at":"2026-05-25T07:31:22.431820+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Contineum reports Q4 2024 net loss of $14.6M, cash $204.8M, runway through 2027","bullets":["Net loss $14.6M in Q4 2024 vs $7.8M in Q4 2023; R&D expenses $13M (+62% YoY).","Cash and equivalents $204.8M at Dec 31, 2024; expects to fund operations through 2027.","Topline data from PIPE-791 Phase 1b PET trial expected Q2 2025; PIPE-307 Phase 2 RRMS data H2 2025.","PIPE-791 Phase 2 proof-of-concept in IPF and PrMS planned H2 2025 pending toxicity studies.","Plan to file IND for CTX-343 in H2 2025; J&J recruiting Phase 2 MDD trial of PIPE-307."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-006457","json":"https://secwatch.observer/filing/0001437749-25-006457.json","markdown":"https://secwatch.observer/filing/0001437749-25-006457.md","text":"https://secwatch.observer/filing/0001437749-25-006457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/0001437749-25-006457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/cont20250214_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T07:31:22.431820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}